Autonomix Medical

Autonomix Medical EBITDA per Employee

The EBITDA per Employee of Autonomix Medical (AMIX) as of Oct 21, 2026 is -5.68 M USD. In the previous year, EBITDA per Employee was -3.86 M USD — a change of 47.00% (lower).

EBITDA per Employee

-5.68 MUSD

YoY

47.00%

Last updated:

EBITDA per Employee of Autonomix Medical is 2026 -5.68 M USD. EBITDA per Employee of Autonomix Medical was 2025 -3.86 M USD. It decreases by 47.00% lower compared to the previous year.

The Autonomix Medical EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2022
-4.53 M USD
Jan 1, 2023
-663,333.33 USD
Jan 1, 2024
-4.01 M USD
Jan 1, 2025
-3.86 M USD
Jan 1, 2026
-5.68 M USD
The Autonomix Medical EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-5.68 MUSD+47.00%
-3.86 MUSD-3.67%
-4.01 MUSD+504.52%
-663,333.33USD-85.36%
-4.53 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autonomix Medical Stock analysis

What does Autonomix Medical do? Autonomix Medical Inc develops medical devices focused on treating peripheral nervous system diseases. The company's technology platform features a catheter-based microchip sensing array capable of detecting peripheral neural signals with up to 1,000 times sensitivity. It is developing a dual-function technology that both detects malfunctioning neural signals and ablates nerves in a single procedure for pain management. The company targets conditions like pancreatic cancer and pancreatitis, which cause severe pain requiring effective solutions. Its Autonomix catheter uses a microchip to convert body analog signals into digital signals for direct transmission to a computer. The company's products include the Autonomix catheter and its underlying technology platform. These are designed for medical professionals treating conditions involving the peripheral nervous system. The primary segments served are patients suffering from pancreatic cancer, pancreatitis, and other peripheral nervous system disorders requiring pain management solutions. The technology platform has potential applications across multiple medical fields including cardiology, renal denervation, and chronic pain management. Autonomix Medical Inc's revenue model is based on developing and commercializing its medical device technology. The company is focused on creating solutions for specific medical conditions where current treatments are inadequate. Its dual-function technology represents a novel approach to pain management by combining detection and ablation capabilities in one procedure. The company's target market includes healthcare providers seeking advanced solutions for peripheral nervous system diseases and chronic pain conditions. Autonomix Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autonomix Medical stock

EBITDA per Employee of Autonomix Medical is -5.68 M USD in 2026.

EBITDA per Employee of Autonomix Medical changed from -3.86 M USD to -5.68 M USD, representing a 47.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Autonomix Medical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Autonomix Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Autonomix Medical

All Key Metrics — Autonomix Medical